uniQure (QURE) AI Stock Analysis

Compare

1,184 Followers

Top Page

uniQure

(NASDAQ:QURE)

Select Model

Neutral 43 (OpenAI - 4o)

Rating:43Neutral

Price Target:

$14.50

▲(4.84% Upside)

uniQure's overall stock score reflects significant financial challenges, with declining revenues and negative profit margins being the most impactful factors. Despite promising clinical advancements and a strong cash position highlighted in the earnings call, the company's financial instability and valuation concerns weigh heavily on the score. Technical analysis provides mixed signals, offering no strong bullish outlook.

Positive Factors

Regulatory Progress

The breakthrough therapy designation for AMT-130 indicates significant regulatory progress, potentially accelerating its path to market and enhancing uniQure's competitive position in treating Huntington's disease.

Strong Cash Position

A robust cash position provides uniQure with the financial flexibility to fund its R&D and commercialization efforts, supporting long-term strategic initiatives and operational stability.

Clinical Advancements

Significant clinical advancements, such as the efficacy of AMT-260, enhance uniQure's pipeline strength, potentially leading to new market opportunities and long-term revenue growth.

Negative Factors

Revenue Decline

The decline in revenue highlights challenges in maintaining sales momentum, which could impact the company's ability to fund operations and invest in growth without additional financing.

High Debt Levels

Elevated debt levels can strain financial resources, limiting uniQure's ability to invest in strategic initiatives and potentially affecting its long-term financial health and stability.

Negative Profit Margins

Negative profit margins reflect operational inefficiencies and ongoing losses, challenging uniQure's ability to achieve profitability and sustain long-term growth without significant cost management or revenue enhancement.

uniQure (QURE) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$761.00M

Dividend YieldN/A

Average Volume (3M)1.11M

Price to Earnings (P/E)―

Beta (1Y)1.57

Revenue Growth-48.25%

EPS Growth33.77%

CountryUS

Employees209

SectorHealthcare

Sector Strength45

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.69

Shares Outstanding54,866,930

10 Day Avg. Volume1,440,999

30 Day Avg. Volume1,106,075

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.19

Enterprise Value/Revenue63.40

Enterprise Value/Gross Profit76.75

Enterprise Value/Ebitda-6.25

Forecast

1Y Price Target

$39.33

Price Target Upside184.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

uniQure Business Overview & Revenue Model

Company DescriptionuniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

How the Company Makes MoneyuniQure generates revenue primarily through the commercialization of its gene therapy products, which include marketed products like Zynteglo for beta-thalassemia and other pipeline therapies in late-stage clinical development. The company also earns revenue from research collaborations and licensing agreements with pharmaceutical and biotechnology companies. These partnerships may include upfront payments, milestone payments based on the achievement of specific developmental or regulatory goals, and royalties on future sales of licensed products. Additionally, uniQure may benefit financially from government grants and funding aimed at supporting innovative research in gene therapy.

uniQure Key Performance Indicators (KPIs)

Any

Revenue by Segment

Revenue by Segment
Highlights income from different business areas, offering insight into which segments drive growth and profitability, and where there might be opportunities or challenges.

Chart InsightsuniQure's revenue from license agreements is showing a gradual recovery, while contract manufacturing revenue has sharply declined to zero in recent quarters. This aligns with the earnings call, which highlighted a significant drop in overall revenue due to reduced collaboration and contract manufacturing. Despite these challenges, uniQure's strong financial position and promising clinical advancements, particularly with AMT-130 for Huntington's disease, suggest a strategic pivot towards high-impact therapeutic developments, potentially offsetting revenue declines in other segments.

Data provided by:

Main Street Data

uniQure Earnings Call Summary

Earnings Call Date:Jul 29, 2025

(Q2-2025)

% Change Since: |

Next Earnings Date:Oct 29, 2025

Earnings Call Sentiment Neutral

The earnings call highlighted significant regulatory and clinical advancements, particularly with AMT-130 and AMT-260, and a strong financial position. However, these positives were tempered by a notable decline in revenue and increased R&D expenses.

Q2-2025 Updates

Positive Updates

Regulatory Progress for AMT-130

AMT-130 received breakthrough therapy designation from the FDA and achieved alignment on statistical analysis and CMC requirements for a BLA submission in early 2026.

Significant Clinical Advances

The company reported a 92% reduction in seizure frequency with AMT-260 for epilepsy and is on track for pivotal data releases for both AMT-130 and AMT-191 in Fabry disease.

Strong Financial Position

uniQure's cash, cash equivalents, and investment securities totaled $377 million as of June 30, 2025, providing funding into the second half of 2027.

Negative Updates

Revenue Decline

Total revenue for Q2 2025 was $5.3 million, a decrease from $11.1 million in the same period of 2024, primarily due to decreases in collaboration and contract manufacturing revenues.

Research and Development Expenses

R&D expenses increased to $35.4 million, up from $33.7 million in the same period of 2024, due to higher external program spend and increased fair value of contingent consideration.

Company Guidance

During the second quarter of 2025 earnings call, uniQure provided detailed guidance on their ongoing clinical advancements and regulatory progress, with a particular focus on AMT-130, a potential first disease-modifying therapy for Huntington's disease. Key metrics shared included the breakthrough therapy designation granted by the FDA in April, alignment with the FDA on the statistical analysis plan and CMC requirements, and the planned BLA submission in Q1 2026. The primary efficacy analysis will use a 3-year change in cUHDRS comparing high-dose patients to a propensity score matched external control. The company also reported an ongoing PPQ campaign and commercial launch preparations for 2026. Revenue for Q2 2025 was $5.3 million, a decrease from $11.1 million in the same period in 2024, with research and development expenses at $35.4 million. Cash, cash equivalents, and investment securities totaled $377 million as of June 30, 2025, positioning the company well for its planned commercialization efforts.

uniQure Financial Statement Overview

Summary

uniQure is facing significant financial challenges with declining revenues, negative profit margins, and a weak balance sheet. The company's high debt levels and negative equity position raise concerns about its financial stability. While there is a slight improvement in free cash flow, the overall financial health of the company is precarious, requiring strategic interventions to improve profitability and strengthen the balance sheet.

Income Statement

Negative

uniQure's income statement reflects significant challenges with declining revenues and negative profit margins. The TTM data shows a sharp revenue decline of 29% and a net profit margin of -13.88%, indicating substantial losses. Despite a high gross profit margin of 82.61% in the TTM, the company struggles with negative EBIT and EBITDA margins, highlighting operational inefficiencies.

Balance Sheet

Negative

The balance sheet reveals a concerning financial position with negative stockholders' equity and a high debt-to-equity ratio of -16.66 in the TTM. This indicates financial instability and potential solvency issues. The return on equity is also negative, reflecting ongoing losses and poor returns for shareholders.

Cash Flow

Negative

uniQure's cash flow statement shows a slight improvement in free cash flow growth at 4.33% in the TTM, but the operating cash flow remains negative, indicating cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that the company is generating enough cash to cover its net losses, but the overall cash flow situation remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.34M	27.12M	15.84M	106.48M	524.00M	37.51M
Gross Profit	11.84M	8.79M	2.21M	103.14M	499.03M	-84.89M
EBITDA	-145.35M	-160.75M	-253.10M	-108.02M	319.00M	-126.97M
Net Income	-199.00M	-239.56M	-308.48M	-126.79M	329.59M	-125.02M
Balance Sheet
Total Assets	584.89M	556.54M	831.69M	704.96M	809.18M	340.39M
Cash, Cash Equivalents and Short-Term Investments	376.97M	367.52M	617.89M	352.84M	556.26M	244.93M
Total Debt	66.70M	66.06M	138.41M	142.89M	135.72M	71.54M
Total Liabilities	588.89M	563.29M	624.02M	228.96M	213.40M	96.49M
Stockholders Equity	-4.00M	-6.75M	207.67M	476.01M	595.78M	243.91M
Cash Flow
Free Cash Flow	-174.26M	-186.10M	-153.08M	-162.75M	270.52M	-144.31M
Operating Cash Flow	-173.44M	-182.73M	-145.93M	-145.06M	287.96M	-134.83M
Investing Cash Flow	114.22M	162.97M	-205.69M	-182.73M	-67.39M	-9.48M
Financing Cash Flow	21.18M	-59.49M	362.72M	1.45M	94.86M	7.44M

uniQure Technical Analysis

Technical Analysis Sentiment

Negative

Last Price13.83

Price Trends

50DMA

15.21

Negative

100DMA

14.87

Negative

200DMA

14.17

Negative

Market Momentum

MACD

-0.31

Positive

RSI

34.91

Neutral

STOCH

6.72

Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Negative. The current price of 13.83 is below the 20-day moving average (MA) of 16.07, below the 50-day MA of 15.21, and below the 200-day MA of 14.17, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 34.91 is Neutral, neither overbought nor oversold. The STOCH value of 6.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QURE.

uniQure Risk Analysis

uniQure disclosed 65 risk factors in its most recent earnings report. uniQure reported the most risks in the "Tech & Innovation" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

uniQure Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	74 Outperform	1.21B	5.90	33.02%	―	799.36%	0.00%
NTLA	58 Neutral	1.85B	-3.68	-59.52%	―	14.99%	14.42%
DAWN	50 Neutral	695.51M	-7.44	0.00%	―	2190.50%	52.85%
QURE	43 Neutral	$761.00M	―	-427.47%	―	-48.25%	33.77%
SYRE	43 Neutral	923.53M	-5.01	0.00%	―	0.00%	-429.68%
RCKT	40 Underperform	343.13M	-1.27	0.00%	―	0.00%	10.36%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

QURE

uniQure

13.83

8.78

173.86%

RCKT

Rocket Pharmaceuticals

3.18

-16.60

-83.92%

SYRE

Spyre Therapeutics

15.29

-14.59

-48.83%

NTLA

Intellia Therapeutics

17.26

-4.20

-19.57%

CVAC

CureVac

5.36

2.27

73.46%

DAWN

Day One Biopharmaceuticals

6.79

-7.47

-52.38%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 16, 2025